California State University, Long Beach

About: California State University, Long Beach is a education organization based out in Long Beach, California, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 10036 authors who have published 13933 publications receiving 377394 citations. The organization is also known as: Cal State Long Beach & Long Beach State.

Experimental studies regarding the possible use of self-curing acrylic in orthopaedic surgery.

Abstract: 1. Self-curing methyl methacrylate causes no more tissue reaction than does Vitallium in the rabbit or monkey. 2. It is not strong enough to be used without reinforcement where there is transverse stress. The strength seems adequate to withstand most compression stresses in the body. Strength is a limiting factor, however. 3. It can be obtained sterile and is available in convenient packages which can be stored for long periods. 4. Heat of polymerization is, at present, a troublesome and limiting factor. It can be controlled by various methods, but this adds to the inconvenience of using the material. 5. It can be molded quickly and easily by use of a negative mold. 6. It will not remain absolutely tight against the bone. This applies not only to plastic but also to steel and Vitallium. 7. Although at the present time, no uses in orthopaedic surgery can be recommended unequivocally, it is believed that it may find a place following more research on the basic material, especially as rgards the heat of polymerization.

Elementary Teachers’ Understanding of Students’ Science Misconceptions: Implications for Practice and Teacher Education

Abstract: This study sought to determine what elementary teachers know about student science misconceptions and how teachers address student misconceptions in instruction. The sample included 30 teachers from California with at least 1-year of experience teaching grades 3, 4, and 5. A semistructured interview was used. The interview transcripts were transcribed and coded under the following categories: definition of misconceptions, sources of misconceptions, development of misconceptions, and teaching strategies for addressing misconceptions. The results suggest that, although most of the teachers are aware of misconceptions, they do not understand how they develop or fully appreciate their impact on their instruction.

Sustainability of Daily Routines as a Family Outcome

Abstract: A mother of a nine-year-old boy says . . . . “Monday, I do carpool duty and so I have to drive into Burbank. I pick up my [age 11] son at 1:00, then we dash over to Burbank and pick up 6 kids and they all get off at different times. Even on days that it’s not my carpool day, I still have an hour and fifteen minutes drive to pick up my son. Some days it’s really hectic. There are days when I have a night class, so we stop and get dinner on the way home, but that’s only one day a week. Then, we do homework, I get the kids bathed and in bed. And we found a new, more appropriate school for [my daughter]. We have an impossible schedule. We had to reshuffle our whole lives. We had to give up a lot to have her go to this school, but I felt like for years we’d given up so much to take care of my son’s therapy and she [the older sister] was miserable. I thought we’ve got to try something else. Every once in a while, I get really tired of the 2 hour drive, and then my daughter will say ‘Please, I’ll do anything, don’t pull me from the school. I’ve never been happier in my life.’ Well, as a result, I get up at 4:30 in the morning, and then I don’t get to bed until after midnight. We probably have the worst life of all the parents in your study. We are going to die young. As far as sleep, we don’t sleep. We exist. I’m lucky, because I’m kind of a night person, but we tend to get sick easily.”

Distinguishing war-related PTSD resulting from perpetration- and betrayal-based morally injurious events.

Abstract: OBJECTIVE We investigated whether potentially morally injurious events (PMIEs) during a combat deployment may lead to PTSD through distinct pathways from danger-based events. We also examined the prevalence of perpetration-based PMIEs, during which service members behaved in ways that violated their own moral values, and betrayal-based PMIEs, during which personal moral expectations were violated by trusted others. METHOD Using a sample of 867 active duty Marines from a single infantry battalion that engaged in heavy ground combat while deployed to Afghanistan, a structural equation model was built to examine the relationships between perpetration- and betrayal-based PMIEs, combat experiences, and peritraumatic dissociation reported at 1 month postdeployment, and guilt/shame, anger, and PTSD symptoms reported at 8 months postdeployment. RESULTS The relationship between betrayal-based PMIEs and PTSD was mediated by anger (β = .14). There was marginal evidence of mediation of the relationship between perpetration-based PMIEs and PTSD by shame and guilt (β = .09), and of the relationship between danger-based combat events and PTSD by peritraumatic dissociation (β = .08). No significant direct relationships were found between any of these 3 types of events and subsequent PTSD. Perceived perpetration and betrayal accounted for PTSD symptoms above and beyond combat exposure. Over a third of the sample reported experiencing perpetration- or betrayal-based PMIEs. CONCLUSIONS The associations of perpetration and betrayal with PTSD, controlling for danger-based combat events, highlight the limitations of conceptualizations and treatments of PTSD based on fear or helplessness as sole etiologic factors. (PsycINFO Database Record

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

Abstract: Importance Metastatic non–small cell lung cancer (mNSCLC) withEGFRexon 20 insertion (EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively targetEGFRex20ins mutations. Objective To evaluate treatment outcomes and safety of mobocertinib in patients with previously treatedEGFRex20ins-positive mNSCLC. Design, Setting, and Participants This 3-part, open-label, phase 1/2 nonrandomized clinical trial with dose-escalation/dose-expansion cohorts (28 sites in the US) and a single-arm extension cohort (EXCLAIM; 40 sites in Asia, Europe, and North America) was conducted between June 2016 and November 2020 (data cutoff date). The primary analysis populations were the platinum-pretreated patients (PPP) cohort and the EXCLAIM cohort. The PPP cohort included 114 patients with platinum-pretreatedEGFRex20ins-positive mNSCLC who received mobocertinib 160 mg once daily from the dose-escalation (n = 6), dose-expansion (n = 22), and EXCLAIM (n = 86) cohorts. The EXCLAIM cohort included 96 patients with previously treatedEGFRex20ins-positive mNSCLC (10 were not platinum pretreated and thus were excluded from the PPP cohort). Interventions Mobocertinib 160 mg once daily. Main Outcomes and Measures The primary end point of the PPP and EXCLAIM cohorts was confirmed objective response rate (ORR) assessed by independent review committee (IRC). Secondary end points included confirmed ORR by investigator, duration of response, progression-free survival, overall survival, and safety. Results Among the PPP (n = 114) and EXCLAIM (n = 96) cohorts, the median (range) age was 60 (27-84) and 59 (27-80) years, respectively; most patients were women (75 [66%] and 62 [65%], respectively) and of Asian race (68 [60%] and 66 [69%], respectively). At data cutoff, median follow-up was 14.2 months in the PPP cohort (median 2 prior anticancer regimens; 40 [35%] had baseline brain metastases), with confirmed ORR of 28% (95% CI, 20%-37%) by IRC assessment and 35% (95% CI, 26%-45%) by investigator assessment; median duration of response by IRC assessment was 17.5 months (95% CI, 7.4-20.3). Median progression-free survival by IRC assessment was 7.3 months (95% CI, 5.5-9.2). Median overall survival was 24.0 months (95% CI, 14.6-28.8). In the EXCLAIM cohort, median follow-up was 13.0 months, with confirmed ORR by IRC assessment of 25% (95% CI, 17%-35%) and by investigator assessment of 32% (95% CI, 23%-43%). The most common treatment-related adverse events were diarrhea and rash. Conclusions and Relevance In this open-label, phase 1/2 nonrandomized clinical trial, mobocertinib was associated with clinically meaningful benefit in patients with previously treatedEGFRex20ins-positive mNSCLC, with a manageable safety profile. Trial Registration ClinicalTrials.gov Identifier:NCT02716116